谱尼测试(300887) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was ¥525,497,117.51, a decrease of 1.50% compared to ¥533,503,557.47 in the same period last year[5] - Net profit attributable to shareholders increased by 68.08% to ¥9,263,189.46 from ¥5,511,208.06 year-on-year[5] - Total operating revenue for Q1 2023 was CNY 525,497,117.51, a decrease of 1.88% from CNY 533,503,557.47 in Q1 2022[22] - Net profit for Q1 2023 reached CNY 9,283,846.83, an increase of 68.5% compared to CNY 5,511,208.06 in Q1 2022[24] - Operating profit for the period was CNY 14,445,749.74, up from CNY 12,681,195.66 in the previous year, reflecting a growth of 13.9%[24] - Total comprehensive income for the period was CNY 9,296,493.91, compared to CNY 5,579,318.07 in Q1 2022, an increase of 66.5%[25] Cash Flow - The net cash flow from operating activities improved significantly to ¥33,250,363.92, a 144.18% increase from a negative cash flow of ¥75,269,395.38 in the previous year[5] - The cash inflow from operating activities increased by 41.28% to ¥698,051,564.48 compared to ¥494,088,097.56 in the same period last year[10] - The net cash flow from investment activities was ¥129,987,377.79, a turnaround from a negative cash flow of ¥94,853,706.42 in the previous year[11] - The company experienced a 95.68% decrease in cash inflow from financing activities, totaling ¥60,310,116.98 compared to ¥1,395,840,401.81 in the same period last year[11] - The cash and cash equivalents decreased by 85.90% to ¥156,942,530.82 from ¥1,113,402,347.78 in the previous year[11] - The cash outflow from operating activities was CNY 664,801,200.56, compared to CNY 569,357,492.94 in the previous year, indicating an increase of 16.7%[26] - The net cash flow from operating activities was CNY 33,250,363.92, a decrease of CNY 75,269,395.38 compared to the previous period[27] - The net cash flow from investing activities was CNY 129,987,377.79, an increase from a negative cash flow of CNY 94,853,706.42 in the previous period[27] - Total cash inflow from financing activities was CNY 60,310,116.98, compared to CNY 1,395,840,401.81 in the previous period[27] - The net cash flow from financing activities was negative at CNY -6,295,161.19, a significant decrease from CNY 1,283,532,979.46 in the previous period[27] - The net increase in cash and cash equivalents was CNY 156,942,530.82, compared to CNY 1,113,402,347.78 in the previous period[27] - The ending balance of cash and cash equivalents was CNY 900,296,214.14, down from CNY 1,614,175,898.71 in the previous period[27] - The company received CNY 1,086,000,000.00 from cash recovered from investments[27] - Cash paid for the acquisition of fixed assets, intangible assets, and other long-term assets was CNY 91,884,112.79[27] - Cash received from borrowings was CNY 37,000,000.00, compared to CNY 158,177,000.37 in the previous period[27] Shareholder Information - The total number of common shareholders at the end of the reporting period is 8,571[12] - The largest shareholder, Song Wei, holds 44.85% of the shares, totaling 128,737,800 shares[12] - The second-largest shareholder, Li Yanggu, holds 11.60% of the shares, totaling 33,291,000 shares[12] - The top ten shareholders collectively hold significant stakes, with the first three shareholders accounting for over 60% of the total shares[12] - The company has a total of 0 preferred shareholders with voting rights restored[14] - The report indicates that there are no shares under pledge, marking a stable financial position for the major shareholders[12] - The company has a total of 7,086,893 shares held by Hong Kong Central Clearing Limited, representing 2.47% of the total shares[12] - The report highlights that Song Wei has controlling stakes in two investment partnerships, further consolidating her influence in the company[13] - The company has not disclosed any relationships or concerted actions among the top ten shareholders beyond the known familial ties[13] - The report does not indicate any changes in restricted shares for the period, suggesting stability in shareholder equity[14] Asset Management - Total assets at the end of Q1 2023 were ¥4,468,759,733.86, down 2.43% from ¥4,579,931,494.76 at the end of the previous year[5] - The total assets decreased from CNY 4,579,931,494.76 at the beginning of the year to CNY 4,468,759,733.86 at the end of Q1 2023[20] - The company’s accounts receivable decreased from CNY 1,086,707,485.55 to CNY 969,880,833.18, a reduction of approximately 10.8%[18] - The company’s inventory increased slightly from CNY 42,094,786.94 to CNY 42,487,819.25, reflecting a growth of about 0.9%[20] - The company’s fixed assets increased slightly from CNY 1,085,040,234.39 to CNY 1,094,257,776.79, indicating a growth of about 0.2%[20] - The company’s total current liabilities decreased from CNY 99,400,000.00 to CNY 86,760,002.63, a decline of approximately 12.9%[20] - Total liabilities decreased to CNY 899,107,761.18 from CNY 1,028,704,755.20, a reduction of approximately 12.6%[22] - The company's total equity increased to CNY 3,569,651,972.68 from CNY 3,551,226,739.56, reflecting a growth of 0.5%[22] Business Operations - The company reported a stable overall business revenue in Q1 2023 despite fluctuations in the medical business segment[17] - The company successfully acquired Hubei Zhongjia Pharmaceutical Co., enhancing its raw material drug GMP production capabilities[17] - The company aims to enhance group management and improve production efficiency to increase per capita output value[17] - Research and development expenses increased to CNY 52,584,381.52, compared to CNY 44,169,647.67 in the same period last year, marking a rise of 18.9%[22] Audit Information - The first quarter report was not audited[28]